Contact Details
Further information on Pharmaxis can be obtained from www.pharmaxis.com.au or by contacting David McGarvey, Chief Financial Officer.
Telephone: +612 9454 7200
david.mcgarvey@pharmaxis.com.au
Pharmaxis Ltd
ABN 75 082 811 630
2/10 Rodborough Road
Frenchs Forest NSW 2086
Quarterly Report to Shareholders Issue 22
Financial Statement Data Unaudited
(International Financial Reporting Standards)
(000 except per share data)
Income Statement Data
Three months ended Nine months ended
31-Mar-09 31-Mar-08 31-Mar-09 31-Mar-09 31-Mar-08 31-Mar-09
A$ A$ US$(1) A$ A$ US$(1)
Revenue from sale of goods 144 136 99 453 330 311
Cost of sales (35) (30) (24) (113) (82) (78)
Gross profit 109 106 75 340 248 233
Interest 927 2,108 637 4,584 5,169 3,151
Other income 132 689 90 276 923 190
Expenses
Research & development 7,193 4,370 4,944 20,780 14,010 14,282
Commercial 1,449 1,154 996 4,339 3,105 2,982
Administration 1,336 1,321 918 4,258 3,785 2,927
Total expenses 9,978 6,845 6,858 29,377 20,900 20,191
Loss before income tax (8,810) (3,942) (6,056) (24,177) (14,560) (16,617)
Income tax expense (1) 2 (1) 27 18 19
Loss for the period (8,809) (3,944) (6,055) (24,204) (14,578) (16,636)
Basic and diluted earnings (loss) per share $ (0.045) (0.020) (0.031) (0.124) (0.078) (0.086)
Depreciation & amortisation 271 253 186 789 772 542
Fair value of options issued under employee plan 650 923 447 1,801 2,604 1,238
Balance Sheet Data
As at
31-Mar-09 30-Jun-08 31-Mar-09
A$ A$ US$(1)
Cash and cash equivalents 85,832 111,842 58,992
Plant & equipment 18,128 3,668 12,459
Total assets 107,457 125,049 73,855
Net assets 96,767 119,121 66,508
Cash Flow Data
Three months ended Nine months ended
31-Mar-09 31-Mar-08 31-Mar-09 31-Mar-09 31-Mar-08 31-Mar-09
A$ A$ US$(1) A$ A$ US$(1)
Cash flows from operating activities (4,515) (4,363) (3,066) (16,343) (16,674) (11,233)
Cash flows from investing activities (3,655) (275) (2,514) (9,742) (2,826) (6,696)
Cash flows from financing activities 31 11 59,571 8
Net increase (decrease) in cash held (8,170) (4,607) (5,580) (26,074) 40,071 (17,921)
Share Data
Ordinary Shares(2)
As at
31-Mar-09 30-Jun-08
Ordinary shares on issue 194,537 194,515
Options over ordinary shares outstanding 13,602 11,536
Notes:
(1) Convenience translation into U.S. dollars from Australian dollars based upon rate on 31 March 2009.
(2) Pharmaxis ordinary shares are traded on the Australian Securities Exchange (PXS) and our ADRs are traded on the Nasdaq Global Market (PXSL).
One Pharmaxis ADR represents 15 Pharmaxis ordinary shares.
|